We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need.
We have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization.
We are currently applying our technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.
We have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization.
We are currently applying our technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $26M
Founded date: 2018
Investors 6
| Date | Name | Website |
| - | Emles Vent... | emlesventu... |
| - | Scientia V... | scientiavc... |
| 24.03.2021 | Y Combinat... | ycombinato... |
| - | Playground... | playground... |
| - | Foobar | foobar.vc |
| 24.03.2021 | Playground... | playground... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.03.2021 | Series A | $26M | Playground... |
Mentions in press and media 6
| Date | Title | Description |
| 31.10.2024 | 1910 Genetics Receives Investment from Accenture Ventures | 1910 Genetics, a Boston, MA-based biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform empowered by laboratory automation, received an investment from Accenture Ventures. The amount of the de... |
| 31.10.2024 | Accenture Invests in 1910 Genetics to Accelerate AI-Powered Drug Discovery | What You Should Know: – Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed... |
| 17.11.2023 | StartUPDATES: New developments from healthcare startups | Harmony Health Foundation has secured a contract with the Tennessee Department of Intellectual and Developmental Disabilities that marks the start of a journey towards expanding access to healthcare for underserved communities. The contract... |
| 20.10.2022 | Slone Partners Places Patrick Genestin as Chief Business Officer at 1910 Genetics | “Patrick Genestin is an extremely accomplished, passionate, and respected business leader with a penchant for establishing strategic partnerships, attracting new investment, and stimulating growth,” said Slone Partners CEO Leslie Loveless. ... |
| 24.06.2021 | 52 Women-Led Startups Driving The Future Of HealthTech And FemTech | The Hero Arm, developed by Open Bionics, cofounded by Samantha Payne, is the world’s first ... [+] clinically approved 3D-printed bionic arm, with multi-grip functionality and empowering aesthetics.Open Bionics |
| 26.03.2021 | 1910 Genetics Raises $26M in Series A Funding | 1910 Genetics, a Cambridge, Mass.-based biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, closed a $22M Series A funding round. The round was co-led by M12 – M... |